Cefazolin sodium, a cephalosporin for parenteral use, was evaluated in vitro and in 26 patients. Cefazolin had activity equivalent to cephalothin against Streptococcus pneumoniae, Staphylococcus aureus, group A streptococci, and Proteus mirabilis. Cefazolin was four-to eightfold more active against Escherichia coli and slightly more active against Klebsiella pneumoniae, whereas cephalothin was slightly more active against indole-positive Proteus species. After a 500-mg dose of cefazolin intramuscularly, peak concentrations in the serum were high enough to inhibit all strains of S. pneumoniae, S. aureus, group A streptococci, E. coli, K. pneumoniae, and P. mirabilis, as well as 60% of strains of Proteus species other than P. mirabilis. All of 26 patients (18 with pneumonia, 6 with urinary tract infection, and 2 with skini infectionis) responided clinically and bacteriologically to cefazolin therapy. There were no major side effects of therapy, and no patient complained of pain at the site of intramuscular injection. Cefazolin is an effective cephalosporin which can be used intramuscularly for therapy of serious bacterial infections. Its major advantages over other cephalosporins are higher, more sustained concentrations in the blood and apparent lack of pain on intramuscular injection.
Cefazolin sodium, a new cephalosporin C antibiotic for parenteral use, is bactericidal against strains of gram-positive and gram-negative bacteria including Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Although cefazolin sodium has a spectrum of activity similar to that of cephalothin, studies in human volunteers have indicated that it gives higher and more sustained concentrations in serum and is less irritating than cephalothin when given by intramuscular or intravenous injection (2).
The present investigation was undertaken to determine the in vitro antibacterial activity of cefazolin sodium and to evaluate it in the treatment of infections in man.
MATERIALS AND METHODS
In vitro susceptibility tests. The following strains of bacteria were isolated from patients: 32 strains of S. aureus, 31 strains each of P. mirabilis and K. pneumoniae, 30 strains of E. coli, 15 straiins of Enterobacter species, 12 strains of Streplococcus pneumoniae, 8 strains of indole-positive Proteus species, and 4 strains of group A streptococci.
The susceptibility of the orgainisms to cefazolin sodium anid cephalothiii sodium was determinied by a dilution method in heart infusion broth at pH 7.4. The antibiotics were diluted in twofold steps in tubes containing 0.5 ml of broth. The bacterial inoculum for each tube was 0.5 ml of a 104 dilution of an 18-hr culture of each strain in heart infusion broth. Studies on S. pneumoniae and group A streptococci were performed in heart infusion broth with 2% sheep red blood cells. The minimal inhibitory concentration was considered to be the lowest concentration of antibiotic that prevented turbidity after 24 hr of incubation at 37 C. At 24 hr, 0.01 ml was removed from each tube without visible growth by use of a sterile platinum loop and streaked on plates of Trypticase soy agar containing sheep red blood cells. After incubation at 37 C for 24 hr, the plates were examined and the lowest concentration of antibiotic that resulted in no growth was taken as the minimal bactericidal concentration.
Determination of antibiotic concentrations in serum and urine. Serum and urine concentrations of cefazolin sodium were determined in patients receiving parenteral cefazolin during the third to the sevenith days of therapy. Blood was obtaiined 0.5, 1, 2, 4, 6, 8, 10 , and 12 hr after administration of a dose of cefazolin sodium.
Urine specimens were obtained by having the patient void before receiving a dose of cefazolin aind collectinlg urine voided during and at the end of the followinig 4-hr interval. Serum was sepa-EVALUATION OF CEFAZOLIN 169 rated and stored at -20 C until the time of assay. Urine was stored at -20 C. The concentrations of cefazolin in serum and urine were determined by a modification of the agar diffusion method described by Wick, with the use of paper discs (3). A volume of 0.25 ml of Bacillus subtilis spore suspension (Difco 04538-59) was mixed with 100 ml of melted heart infusion agar. Pour plates were made with 10 ml for each plate and were allowed to harden. Sterile paper discs were submerged in known concentrations of cefazolin sodium freshly prepared in pooled human serum and in the sera to be tested. The 
RESULTS
In vitro antibacterial activity of cefazolin sodium and comparison with cephalothin sodium. Cefazolin sodium and cephalothin sodium had equivalent in vitro activity against S. pneurnoniae, S. aureus, group A streptococei, anud P. mirabilis. Both antibiotics inhllibited all straiins of S. pneumoniae and group A streptococci at a concentration of 0.2 Mg/ml and all strains of S. aureus at 0.8 Mug/ml (Fig. 1 ). All P. mirabili8 strains were inhibited by 12.5 ;sg of cephalothin/ml and 25 ,ug of cefazolin/ml (Fig. 2) . Strains of K. pneumoniae were slightly more susceptible to cefazolin than to cephalothin (Fig. 3 ). All strains of K. pneumoniae were inhibited by 25 ug of both drugs/ml; however, 90% of strains of K. pneumoniae were inhibited by 3.1 ;.g of cefazolin/ml and only 55% of strains were inhibited by the same concentration of cephalothin. Cefazolin sodium was much more active against E. coli than cephalothin sodium (Fig. 4) . All E. coli strains tested were inhibited by 6.3 Mg of cefazolin/ml, whereas only 46% were inhibited by the same concentration of cephalothin. Proteus species other than P. mirabilis, although relatively resistant to both drugs ( Cefazolin sodium concentrations in serum and urine. As shown in Table 1 , mean serum concentrations of cefazolin after a 500-mg intramuscular dose in patients with normal serum creatinine concentration were 34.4 jug/ml (20.5 to 47 pg/ml) at 0.5 hr, 36.4 JAg/ml (17.8 to 56 ,ug/ml) at 1 hr, 25.6 ,ug/ml (16.5 to 45 ,ug/ml) at 2 hr, and 16.1 jug/ml (8.8 to 21 yLg/ml) at 4 hr. In two patients, levels of drug were still measurable in the serum at 12 hr. In patients with abnormal renal function (serum creatinine greater than 1.2 mg/100 ml), the serum concentrations of cefazolin were more sustained.
During the 4 hr after administration of 500 mg of cefazolin intramuscularly, concentrations in the urine ranged from 380 to 3,600 ,ug/ml. During this 4-hr collection, approximately 43 to 81% of injected cefazolin activity was recovered in the urine in patients with normal renal function, and 22 to 43% of the injected activity was recovered in patients with abnormal renal function (excluding one patient who received a 1-g dose).
Clinical studies with cefazolin sodium. The clinical data are summarized in Table 2 . The ages of the 26 patients ranged from 30 to 88 years with a mean of 60 years, and 18 of them were males.
Patients with pneumonia. In 14 of the 18 patients with pneumonia, the infecting organism was S. pneumoniae (patients 1-14). Response to therapy was prompt in the 14 patients, and all 100 _ Creatinine (mg/ 100 ml) 0.9 0.9 0.9 0.9 1.1 1.1 1.1 0.9
1.7 1.6 1.6 2.9 1.4 1.4 2.2 1.3
1.6
VOL. 3, 1973 on mirabili and is equivalent in activity against P. mnirabilis. The major advantages of cefazolin over cephalothin would seem to be that of higher, more sustained concentrations in serum and the lack of pain after intramuscular injection.
The present investigation has demonstrated that cefazolin reaches high concentrations in the blood and urine after parenteral administration. The mean serum concentration 1 hr after intramuscular injection of 500 mg of cefazolin was 36.4 ug/ml in patients with normal renal function (serum creatinine, 1.1 mg/100 ml or less). Four hours after intramuscular injection of 500 mg of cefazolin, the mean serum concentration was 16.1 pg/ml. This compares with a mean peak concentration of about 8 pug/ml at 0.5 hr and about 1 ,ug/ml at 4 hr after intramuscular injection of 500 mg of cephalothin (1). There were still measurable levels of cefazolin present 12 hr after injection. With cephalothin, there were no measurable serum levels after 6 hr. The peak serum concentrations of cefazolin were high enough to inhibit all strains of S. pneumoniae, S. aureus, group A streptococci, E. coli, K. pneumoniae, and P. mirabilis, as well as 60% of strains of Proteus species other than P. mirabili. All strains of E. coli, P. mirabilis, and K. pneumoniae were inhibited by concentrations obtained in the urine.
In this study, all of the 26 patients responded clinically and bacteriologically to cefazolin therapy. The relapses which occurred in three of six patients with urinary tract infection were probably related more to the nature of the patients than to failure of therapy. One of these patients had carcinoma of the urinary bladder and another had prostatic hypertrophy, both of which caused obstructive uropathy.
The eosinophilia observed in 4 of the 26 patients was probably related to cefazolin. The elevation of BUN in one patient was thought to be due to hypotension following a respiratory arrest. This patient also had a rise in alkaline phosphatase and SGPT, also probably related to hypotension. Two other patients had unexplained rises in alkaline phosphatase. The drop in hematocrit in two patients was probably caused by hydration. The most bothersome side effect was drug fever in one patient which promptly disappeared at the end of therapy.
From these studies, it can be concluded that cefazolin is an effective cephalosporin which can be used intramuscularly for therapy of serious bacterial infections. It results in higher and more sustained blood levels than cephalothin and has the advantage of being well tolerated intramuscularly. 
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